For the quarter ending 2025-09-30, CTNM made $4,058K in revenue. -$12,674K in net income. Net profit margin of -312.32%.
| Income Statement | 2025-09-30 | 2025-06-30 | 2024-12-31 | 2024-09-30 |
|---|---|---|---|---|
| Research and development | 10,992 | - | 10,397 | 9,728 |
| General and administrative | 3,940 | - | 3,092 | 3,246 |
| Total operating expenses | 14,932 | - | 13,488 | 12,974 |
| Loss from operations | -14,932 | - | -13,488 | -12,974 |
| Other expense, net | - | - | -26 | -34 |
| Interest income | - | - | 2,082 | 2,741 |
| Change in fair value of warrant liability | - | - | 39 | - |
| Total other income, net | 2,410 | - | 1,997 | 2,707 |
| Income (loss) before income taxes | - | - | -11,491 | -10,267 |
| Other segment items | - | 167 | - | - |
| Research and development-Unallocated Internal Costs | - | 3,338 | - | - |
| Research and development-PIPE791 | - | 6,178 | - | - |
| Research and development-PIPE307 | - | 2,160 | - | - |
| Research and development-Discovery Programs | - | 1,328 | - | - |
| Research and development-CTX343 | - | 1,059 | - | - |
| Provision for income taxes | - | - | 0 | - |
| Interest income | - | 2,029 | - | - |
| Net loss | -12,792 | - | -11,491 | -10,267 |
| General and administrative | - | 3,839 | - | - |
| Unrealized gain on marketable securities | 118 | - | -328 | 688 |
| Net loss | - | -16,040 | - | - |
| Comprehensive loss | -12,674 | - | -11,819 | -9,579 |
| Diluted eps | - | - | -0.695 | -0.4 |
| Diluted average shares | - | - | -14,866,371.5 | 25,730,014 |
| Basic and diluted (in dollars per share) | -0.45 | - | -0.695 | -0.4 |
| Weighted-average shares of common stock outstanding, basic and diluted (in shares) | 28,115,548 | - | -14,866,371.5 | 25,730,014 |
Contineum Therapeutics, Inc. (CTNM)
Contineum Therapeutics, Inc. (CTNM)